Aeterna Zentaris
AEZS
$2.14
Share price
1.60%
Change (1 day)
-44.30%
Change (1 year)
Categories
P/S ratio for Aeterna Zentaris (AEZS)
P/S ratio as of December 2023 (TTM): 1.52
According to Aeterna Zentaris's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.52072. At the end of 2023 the company had a P/S ratio of 1.78.
P/S ratio history for Aeterna Zentaris from 2001 to 2023
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2023 | 1.78 | -34.98% |
| 2022 | 2.74 | -82.64% |
| 2021 | 15.8 | 117.3% |
| 2020 | 7.27 | -78.77% |
| 2019 | 34.2 | 1778.01% |
| 2018 | 1.82 | -95.68% |
| 2017 | 42.2 | -8.16% |
| 2016 | 46.0 | -43.41% |
| 2015 | 81.3 | -97.7% |
| 2014 | > 1000 | 34841.35% |
| 2013 | 10.1 | 465.19% |
| 2012 | 1.79 | -59.18% |
| 2011 | 4.39 | -15.22% |
| 2010 | 5.18 | 539.49% |
| 2009 | 0.8099 | 19.55% |
| 2008 | 0.6774 | -65.25% |
| 2007 | 1.95 | -62.47% |
| 2006 | 5.19 | 363.04% |
| 2005 | 1.12 | -25.67% |
| 2004 | 1.51 | 24.21% |
| 2003 | 1.22 | -48.05% |
| 2002 | 2.34 | -67.21% |
| 2001 | 7.13 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 3.81 | 150.50% | 🇨🇭 Switzerland |
 Sanofi SNY | 2.37 | 55.56% | 🇫🇷 France |
 Bristol-Myers Squibb BMY | 2.27 | 49.57% | 🇺🇸 USA |
 Spectrum Pharmaceuticals
SPPI | 8.22 | 440.31% | 🇺🇸 USA |
 Halozyme Therapeutics HALO | 6.75 | 343.95% | 🇺🇸 USA |